African Journal of
Medical and Health Sciences

OFFICIAL PUBLICATION OF THE FEDERAL TEACHING HOSPITAL, ABAKALIKI, NIGERIA
  • Abbreviation: Afr. J. Med. Health Sci.
  • Language: English
  • ISSN: 2384-5589
  • DOI: 10.5897/AJMHS
  • Start Year: 2017
  • Published Articles: 78

Full Length Research Paper

Primary and secondary resistance to first-line anti-tuberculosis medications at the Institute Pasteur Bangui, Central African Republic

Alain Farra
  • Alain Farra
  • National Reference Laboratory for Tuberculosis, Institut Pasteur in Bangui, Central African Republic.
  • Search for this author on:
  • Google Scholar
Boris Jolly
  • Boris Jolly
  • National Reference Laboratory for Tuberculosis, Institut Pasteur in Bangui, Central African Republic.
  • Search for this author on:
  • Google Scholar
Gilles Ngaya
  • Gilles Ngaya
  • Medical Testing Laboratory, Institut Pasteur in Bangui, Central African Republic.
  • Search for this author on:
  • Google Scholar
Herve Gando
  • Herve Gando
  • National Tuberculosis Control Program, CAR Ministry of Health, BP: 883, Central African Republic.
  • Search for this author on:
  • Google Scholar
Aristide Desire Komamgoya-Nzonzon
  • Aristide Desire Komamgoya-Nzonzon
  • TB/HIV/Malaria and Viral Hepatitis WHO Focal Point, Bangui, Central African Republic.
  • Search for this author on:
  • Google Scholar
Alexandre Manirakiza
  • Alexandre Manirakiza
  • Epidemiology Department, Institut Pasteur in Bangui, Central African Republic.
  • Search for this author on:
  • Google Scholar


  •  Received: 23 October 2020
  •  Accepted: 28 January 2021
  •  Published: 31 March 2021

Abstract

The emergence and spread of anti-tuberculosis-resistant strains of Mycobacterium tuberculosis presently represents a real challenge to the WHO's End TB by 2035 strategy. Through this study, we wanted to determine the current prevalence of primary and secondary resistance to first-line anti-tuberculosis drugs at the Pasteur Institute in Bangui. Cultures and sensitivity tests were carried out for 6 months (July - December 2018) in 225 consenting tuberculosis patients. The prevalence was 4.1% in new cases and 25.2% in retreatment cases. Previous exposure to treatment has been the risk factor for the development of drug resistance. The resistance profile showed that 73.2% of patients were multidrug resistant (MDR) and 34.2% of retreatment patients presented resistance to all first-line anti-tuberculosis drugs; moreover, of the three new cases with resistance to anti-TB medicines, two showed multiple resistance, associating rifampicin and isoniazid. Surveillance of resistance to anti-tuberculosis drugs at the national level is necessary because it will allow better control of tuberculosis in the Central African Republic.

Key words: News cases, retreatement, MDR-TB, Risk factor, Bangui.

Copyright © 2024 Author(s) retain the copyright of this article.

This article is published under the terms of the Creative Commons Attribution License 4.0

Back to Vol. 20 No. 3
Back to articles
SUBSCRIBE TO RSS
SUBMIT MANUSCRIPT
CONFERENCES